Peptide LibraryCerluten
Cerluten is a khavinson peptide bioregulator. The Khavinson bioregulator hypothesis holds that short peptides extracted from a given tissue act preferentially on that same tissue, with proposed effects on gene expression and protein synthesis. Most supporting work comes from a single research group, is published largely in Russian-language journals, and has not been independently replicated in controlled human trials.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
Vendor price snapshot
None of these listings has a price per mg to compare. From public vendor listings; confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 1
- Listed offers
- 2
- Price per mg
- —
Research summary
Peptide preparation derived from brain and central nervous system tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Cerluten itself is indexed in PubMed, controlled or otherwise; the studies cited here are class-level work on short peptide bioregulators.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Cerluten profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Cerluten dosage: no established human dose
Cerluten has no established human dosage. It is sold as oral capsules described as a brain and nervous system peptide bioregulator. No study of Cerluten is indexed in PubMed under that name, and no trial is registered on ClinicalTrials.gov. The only related evidence is laboratory work on other peptides from the same Russian research tradition.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Cerluten is marketed in the Khavinson bioregulator tradition as a peptide complex from brain and nervous system tissue. Its composition is not published in an indexed source, so it cannot be matched to any studied peptide. The series literature comes mostly from one research group in Russian-language journals. No animal or human study of Cerluten itself could be found, so nothing here establishes a human dose, route or interval.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Class-level (analog evidence) — other Khavinson peptides in rat tissue explants (2001)Preclinical · Cell and tissue culture study of related synthetic peptides (analog evidence)Studied an analog, not Cerluten itself | Explants of rat brain cortex, subcortical structures, liver and thymus in organotypic culture | Not stated in the indexed abstract; tested in tissue culture, not given to an animal or a person | In vitro, added to culture | — | — | Cortagen, Epithalon, Livagen and Vilon each stimulated growth of explants from the tissue their source peptide complex came from. Cortagen, the peptide in this study linked to brain cortex, is a different synthetic peptide; Cerluten itself was not tested. | Tissue-specific effects of peptides. Bull Exp Biol Med. 2001. |
Where sources disagree
- No indexed study or registered trial reports a dose of Cerluten, so intake directions given for it have no verifiable primary source.
- Cerluten is a capsule product, while other brain-linked preparations in this series (such as the synthetic peptide Cortagen) are separate compounds with their own literature.
- Evidence for other Khavinson peptides or extracts is not evidence for this product. Each peptide or extract in the series is a different preparation.
Science
Mechanism of Action
The Khavinson bioregulator hypothesis holds that short peptides extracted from a given tissue act preferentially on that same tissue, with proposed effects on gene expression and protein synthesis. Most supporting work comes from a single research group, is published largely in Russian-language journals, and has not been independently replicated in controlled human trials. Claims specific to the brain and central nervous system preparation should be read as marketing rather than established pharmacology.
Studies
- Peptides and Ageing (class-level)
- Tissue-specific effects of peptides (class-level)
- Peptide bioregulation of aging: results and prospects (class-level evidence)
- Mechanisms underlying geroprotective effects of peptides (class-level evidence)
- Epigenetic mechanisms of peptide-driven regulation and neuroprotective protein FKBP1b (class-level evidence)
Regulatory & research status
Cerluten is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Research status | Research-only compound; no approval pathway listed |
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
—
Cerluten side effects
No side effects listed yet for this entry.
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Cerluten: frequently asked questions
What is Cerluten?
Peptide preparation derived from brain and central nervous system tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Cerluten itself is indexed in PubMed, controlled or otherwise; the studies cited here are class-level work on short peptide bioregulators.
How does Cerluten work?
The Khavinson bioregulator hypothesis holds that short peptides extracted from a given tissue act preferentially on that same tissue, with proposed effects on gene expression and protein synthesis. Most supporting work comes from a single research group, is published largely in Russian-language journals, and has not been independently replicated in controlled human trials.
Is Cerluten FDA approved?
No. Cerluten is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Cerluten?
Compounds most often compared with Cerluten include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Class-level evidence — Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett, 2002External reference
- Class-level evidence — Tissue-specific effects of peptides. Bull Exp Biol Med, 2001External reference
- Class-level evidence — Peptide bioregulation of aging: results and prospects — Biogerontology, 2010External reference
- Class-level evidence — Mechanisms underlying geroprotective effects of peptides — Bull Exp Biol Med, 2002External reference
- Class-level evidence — Epigenetic mechanisms of peptide-driven regulation and neuroprotective protein FKBP1b — Mol Biol (Mosk), 2019External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 3
This Cerluten profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Cerluten research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →